HK1149176A1 - 針對流感病毒的多種亞型的疫苗 - Google Patents

針對流感病毒的多種亞型的疫苗

Info

Publication number
HK1149176A1
HK1149176A1 HK11103561.0A HK11103561A HK1149176A1 HK 1149176 A1 HK1149176 A1 HK 1149176A1 HK 11103561 A HK11103561 A HK 11103561A HK 1149176 A1 HK1149176 A1 HK 1149176A1
Authority
HK
Hong Kong
Prior art keywords
influenza virus
vaccines against
against multiple
multiple subtypes
subtypes
Prior art date
Application number
HK11103561.0A
Other languages
English (en)
Inventor
‧德拉奇亞-阿科利
‧韋納
嚴健
‧雷蒂
Original Assignee
賓夕法尼亞大學托管會
製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賓夕法尼亞大學托管會, 製藥有限公司 filed Critical 賓夕法尼亞大學托管會
Publication of HK1149176A1 publication Critical patent/HK1149176A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK11103561.0A 2007-11-12 2011-04-07 針對流感病毒的多種亞型的疫苗 HK1149176A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98728407P 2007-11-12 2007-11-12
PCT/US2008/083281 WO2009073330A2 (en) 2007-11-12 2008-11-12 Novel vaccines against multiple subtypes of influenza virus

Publications (1)

Publication Number Publication Date
HK1149176A1 true HK1149176A1 (zh) 2011-09-30

Family

ID=40718429

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103561.0A HK1149176A1 (zh) 2007-11-12 2011-04-07 針對流感病毒的多種亞型的疫苗

Country Status (10)

Country Link
US (4) US9592285B2 (zh)
EP (1) EP2217064A4 (zh)
JP (5) JP5705545B2 (zh)
KR (1) KR101255419B1 (zh)
CN (1) CN101877965B (zh)
AU (1) AU2008331673B2 (zh)
CA (1) CA2705461A1 (zh)
HK (1) HK1149176A1 (zh)
MX (2) MX2010005229A (zh)
WO (1) WO2009073330A2 (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
EP2498814B1 (en) 2009-11-02 2015-09-09 The Trustees of the University of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
CN101892248B (zh) * 2010-04-29 2012-04-18 王世霞 禽流感h5 ha抗原的单克隆抗体
WO2012036993A1 (en) * 2010-09-14 2012-03-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
CA2827080C (en) 2011-02-11 2022-09-20 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
BR112013032723A2 (pt) 2011-06-20 2017-01-31 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CA2863981A1 (en) 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
WO2013122827A1 (en) 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
RU2017141447A (ru) * 2012-03-30 2019-02-13 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
IN2015DN03070A (zh) * 2012-11-27 2015-10-02 Univ Pittsburgh
JP2014131987A (ja) * 2012-12-05 2014-07-17 Samsung R&D Institute Japan Co Ltd アミン誘導体、有機発光材料及びそれを用いた有機エレクトロルミネッセンス素子
CN105307678A (zh) 2013-03-12 2016-02-03 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的改进疫苗及其使用方法
US9987347B2 (en) 2013-03-15 2018-06-05 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of dengue virus
JP6457481B2 (ja) * 2013-03-15 2019-01-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア デングウイルスの複数のサブタイプに対する新規ワクチン
US10022434B2 (en) 2013-03-15 2018-07-17 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN114045295A (zh) 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
CN103421843B (zh) * 2013-07-29 2015-12-09 中国农业科学院哈尔滨兽医研究所 编码h5n1亚型禽流感同义血凝素(ha)蛋白以及同义神经氨酸酶(na)蛋白的基因及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN106039303A (zh) * 2016-06-20 2016-10-26 华南农业大学 一种h5亚型禽流感dna疫苗及其制备方法
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
JP7329530B2 (ja) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法
CA3106400A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CN113423718A (zh) * 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR102326037B1 (ko) 2019-04-18 2021-11-12 충북대학교 산학협력단 H5 인플루엔자를 치료 또는 예방하기 위한 펩타이드 및 이를 암호화하는 코돈 최적화 서열, 및 이를 이용한 백신
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
WO2023019274A1 (en) * 2021-08-13 2023-02-16 Purdue Research Foundation Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy
CN116751306A (zh) * 2023-03-17 2023-09-15 上海生物制品研究所有限责任公司 一种编码通用流感的mRNA疫苗及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
WO1999024640A1 (fr) 1997-11-12 1999-05-20 Hitachi, Ltd. Procede de surveillance de corps etrangers dans un dispositif de traitement par plasma
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
JP2005525792A (ja) * 2001-12-21 2005-09-02 ゲンパト７７ ファーマコジェネティクス エージー 免疫関連疾患および他の疾患に用いる治療的抗ｔｉｒｃ７抗体
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
KR101229202B1 (ko) * 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
US20040175727A1 (en) * 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
KR101251902B1 (ko) * 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
CA2567324C (en) * 2003-05-30 2012-01-03 Advisys, Inc. Devices and methods for biomaterial production
US20060024670A1 (en) * 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
GB0507997D0 (en) 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
EP1851238A4 (en) * 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
CN101166827B (zh) * 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc RECOMBINANT GRIP VACCINES
US20070116717A1 (en) * 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
AU2006304640B2 (en) * 2005-10-18 2012-10-11 Novavax, Inc. Functional influenza virus like particles (VLPs)
KR20090034297A (ko) 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신
CN1810961B (zh) 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
CA2541872A1 (en) * 2006-04-26 2007-10-26 Institut Pasteur H5 pseudotyped viruses and uses thereof
CN105132439A (zh) * 2006-07-28 2015-12-09 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
PT2066399T (pt) * 2006-10-17 2019-01-11 Inovio Pharmaceuticals Inc Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
WO2008091657A1 (en) * 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
WO2008124331A1 (en) * 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Also Published As

Publication number Publication date
US9592285B2 (en) 2017-03-14
WO2009073330A2 (en) 2009-06-11
AU2008331673B2 (en) 2014-12-11
JP2017210482A (ja) 2017-11-30
JP6047610B2 (ja) 2016-12-21
EP2217064A4 (en) 2012-10-03
EP2217064A2 (en) 2010-08-18
JP5705545B2 (ja) 2015-04-22
JP2016052333A (ja) 2016-04-14
KR20100096164A (ko) 2010-09-01
US20090169505A1 (en) 2009-07-02
WO2009073330A3 (en) 2010-01-07
CN101877965B (zh) 2014-08-20
AU2008331673A1 (en) 2009-06-11
MX2010005229A (es) 2010-11-05
CA2705461A1 (en) 2009-06-11
JP6195943B2 (ja) 2017-09-13
JP2011506272A (ja) 2011-03-03
US20180333480A1 (en) 2018-11-22
KR101255419B1 (ko) 2013-04-17
US20170165353A1 (en) 2017-06-15
US20110305664A1 (en) 2011-12-15
JP2013247962A (ja) 2013-12-12
JP6549194B2 (ja) 2019-07-24
US10076565B2 (en) 2018-09-18
JP2015120753A (ja) 2015-07-02
MX339241B (es) 2016-05-18
CN101877965A (zh) 2010-11-03
US8133723B2 (en) 2012-03-13

Similar Documents

Publication Publication Date Title
HK1149176A1 (zh) 針對流感病毒的多種亞型的疫苗
IL262734B (en) Influenza virus suppressant compounds and uses thereof
IL262123A (en) Influenza virus vaccines and their uses
ZA201004688B (en) Novel vaccines against multiple subtypes of dengue virus
EP2118323A4 (en) DETECTION OF INFLUENZA VIRUS
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
HK1143085A1 (en) Low-additive influenza vaccines
HK1199211A1 (zh) 流感病毒疫苗及其用途
IL196024A0 (en) Influenza vaccine
PL2422810T3 (pl) Szczepionka przeciw grypie
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
ZA201103175B (en) Vaccine composition for use against influenza
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA200809056B (en) Influenza virus vaccine
BRPI0821034A2 (pt) Vírus influenza modificado
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
EP2117589A4 (en) FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
ZA201100962B (en) Influenza vaccines
EP2368899A4 (en) VACCINE AGAINST AVIAN INFLUENZA
EP2327714A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST FLUID VIRUS INFECTION
EP2310030A4 (en) NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUSES
HK1177692A1 (zh) 新的流感病毒
EP2240199A4 (en) INFLUENZA VACCINES
ZA200900062B (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191110